Skip to main content
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
19.97
-2.55 (-11.32%)
At close: Apr 4, 2025, 4:00 PM
21.00
+1.03 (5.16%)
After-hours: Apr 4, 2025, 7:35 PM EDT

Apellis Pharmaceuticals Revenue by Segment
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Product
709.95M 657.44M 580.05M 490.56M 366.28M 247.28M 165.77M 91.78M
Product Growth
93.83% 165.87% 249.90% 434.47% 462.71% 352.49% 292.02% 236.74%
Collaboration License and Other
71.41M 57.78M 48.74M 33.51M 30.31M 25.60M 18.76M 14.10M
Collaboration License and Other Growth
135.62% 125.73% 159.80% 137.61% 193.41% -56.17% -65.49% -73.73%

Product Revenue by Segment
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Syfovre
611.85M 558.35M 481.67M 394.39M 275.28M 160.98M 85.70M 18.36M
Syfovre Growth
122.26% 246.84% 462.03% 2,048.08% - - - -
Empaveli
98.13M 99.13M 98.42M 96.21M 91.04M 86.34M 80.14M 73.49M
Empaveli Growth
7.79% 14.81% 22.81% 30.91% 39.72% 57.93% 89.58% 169.78%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.